LAUSR

words: “BIM” or “BCL-2-like 11” or “BCL2-like 11” or “BCL-2 like 11” AND “polymorphism” AND “lung cancer”. We collected data from the all full-published English papers, not any meeting or conference abstract. A thorough literature search was undertaken using the following databases: PubMed (http://www.ncbi.nlm.nih. gov), Embase (http://www.embase.com), and Science Direct (http://www.sciencedirect.com) databases. Abstracts were scrutinized, and full articles were analyzed. The literature retrieval was performed by two independent authors. And no language or date restrictions were found in literature collection. Results: Sixteen cohort studies, covering 4393 WT and 916 BIM deletion patients were included. Overall, BIM deletion polymorphism was associated with significantly shorter progression-free survival (PFS) and slightly shorter overall survival (OS), compared to the WT group. Moreover, patients with BIM deletion polymorphism showed significantly inferior response to EGFR TKIs. Conclusion: Our analysis confirmed that lung cancer patients harboring the BIM deletion have inferior survival and TKI responses. Examination of the novel biomarker BIM deletion in lung cancer patients, especially for the EGFR mutant cohort, could provide some prognostic utility.